Callan JMB announced it has signed a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech, a clinical-stage biopharmaceutical company with a diversified therapeutic pipeline. Callan JMB will serve as independent third-party overseer of Attune 's manufacturing, quality assurance and control, and deployment operations. Under the agreement, Callan JMB will provide federal oversight services, including manufacturing quality assurance and independent batch record review, Biomedical Advanced Research and Development Authority contract compliance, Food and Drug Administration audit readiness and mock inspections, milestone tracking, and federal reporting, supply chain governance and supplier qualification, and Strategic National Stockpile deployment coordination.
Callan JMB Inc. is a vertically integrated logistics and fulfillment company, which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. The Company provides comprehensive alternatives to all logistics solutions and services utilized for frozen shipping in the life sciences industry (personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). Its Ship2Q ultraviolet disinfection process (Safe Hygienic Irradiation Performance Process & Qualification) ensures fitness, thermal reliability, and cleanliness of the system components within the manufacturers specifications equal to new off-the-shelf shipper systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
